Ascletis Pharma Inc.
ASCLFOTCHealthcare● Active
$1.35
+$0.03(+2.27%)
Market Cap$1.4B
P/E Ratio—
52W High$2.5
52W Low$0.9325
Ascletis Pharma Inc. (ASCLF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ASCLF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($350.59M) | ($300.94M) | ($144.72M) | ($314.84M) | ($199.02M) |
| Depreciation & Amort. | $17.16M | $20.45M | $18.48M | $30.19M | $29.55M |
| Stock-Based Comp. | $0.00M | $3.00M | $1.33M | $3.19M | $7.13M |
| Change in Working Capital | $1.97M | $13.79M | $38.53M | $33.81M | ($10.18M) |
| Net Cash from Operations | ($329.25M) | ($341.58M) | ($144.16M) | ($142.45M) | ($146.93M) |
| Investing Activities | |||||
| Capital Expenditure | ($1.60M) | ($2.15M) | ($19.16M) | ($14.40M) | ($7.20M) |
| Purchases of Investments | ($556.14M) | ($637.52M) | ($997.22M) | ($1762.40M) | ($601.98M) |
| Sales of Investments | $1124.03M | $1497.43M | $1166.10M | $479.32M | $332.20M |
| Net Cash from Investing | $566.01M | $978.91M | $149.84M | ($1297.39M) | ($274.49M) |
| Financing Activities | |||||
| Common Stock Repurchased | ($79.47M) | ($98.53M) | ($78.96M) | $0.00M | ($28.69M) |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($4.73M) | ($2.39M) | ($2.22M) | ($2.28M) |
| Net Cash from Financing | $336.32M | ($103.51M) | ($81.50M) | ($1.42M) | ($31.10M) |
| Free Cash Flow | |||||
| Free Cash Flow | ($330.85M) | ($343.73M) | ($163.32M) | ($156.85M) | ($154.13M) |
| FCF Margin %(computed) | — | — | -288.57% | -289.99% | -200.49% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CNY · M
Explore more Ascletis Pharma Inc. data
About Ascletis Pharma Inc. (ASCLF) Cash Flow Statement
Ascletis Pharma Inc. generated operating cash flow of ($0.33B) and free cash flow of ($0.33B) for 2025 — a FCF margin of -16746.39%. Capital expenditure was ($0.00B).
Frequently asked questions
ASCLF · 4 questionsAscletis Pharma Inc. generated free cash flow of ($0.33B) for 2025, up 3.7% year-over-year.
ASCLF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10